Articles related to Cardiology

Phase 3 TRIUMPH-1 trial results for retatrutide, a triple hormone agonist targeting GIP, GLP-1, and glucagon receptors, showed up to 28.3% mean weight loss at 80 weeks and 30.3% in patients with BMI ≥35 at 104 weeks — the largest weight reduction reported in a medication trial to date, per Lilly’s press release.

Synthetic DNA molecules known as polypurine reverse Hoogsteen hairpins reduced PCSK9 expression and lowered LDL cholesterol by approximately 50% in preclinical models, representing an early-stage gene-targeted approach distinct from existing monoclonal antibody and RNA interference strategies.

An observational study of 17,088 UK Biobank participants found that substantial cardiovascular risk reduction required 560–610 minutes of moderate to vigorous physical activity per week, roughly three to four times current public health recommendations.

The FDA approved baxdrostat (Baxfendy), a selective oral aldosterone synthase inhibitor, as an adjunctive treatment for adults with hypertension uncontrolled on at least two existing antihypertensive agents, including a diuretic.

A Senate investigative report alleged that federal health officials received early signals of myocarditis and pericarditis following mRNA COVID-19 vaccination in adolescents and young adults months before public advisories were issued, citing internal agency communications and subpoenaed HHS documents.

A 61-year-old man presenting with chest pain and the de Winter ECG pattern was found on emergency angiography to have proximal left circumflex artery occlusion rather than the classically associated LAD occlusion, representing only the second such case reported in the literature.